JCNN News Summaries - Japan Corporate News Network - Daiichi Products Covered by National Health Insurance
Tokyo, Apr 5, 2006 - (JCN) - Some of Daiichi Pharmaceutical’s Intrathecal Baclofen therapy products are now listed for national health insurance reimbursement. One of them is the SynchroMed infusion system that comprises of the SynchroMed EL pump and the InDura catheter.
Intrathecal Gabalon (baclofen) and the SynchroMed system are used to treat severe spasticity in patients if conventional treatments don’t. The system involves a surgically implanted pump that automatically delivers baclofen directly to the spinal cord when needed.
Dosages delivered can be individually tailored are generally less than if taken orally. The SynchroMed system markedly reduces severe spasticity.
Most Popular
How To Become A Time Champion
Time Management Tip: You Have To Track The Hand-offs
10 Jobs That Pay $30 An Hour
The Global CFO Study 2008
Top Ten Public Speaking Tips
SynchroMed infusion and Intrathecal Gabalong have been used to treat some 50,000 patients worldwide.
c 2006 Japan Corporate News Network. All rights reserved.
Provided by ProQuest Information and Learning Company. All rights Reserved.
